Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233098 · ClinicalTrials.gov registry record
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 6
- Enrollment target
NCT05233098 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 6 participants.
The verdict
NCT05233098 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
Interventions
- DEVICE Technetium-99m macroaggregated albumin (Tc-99m MAA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-06-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05233098
The ClinicalTrials.gov registry entry for NCT05233098 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Technetium-99m macroaggregated albumin (Tc-99m MAA) is the first listed.
NCT05233098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05233098 about?
NCT05233098 is a clinical study titled "TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.". The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
What is the current status of trial NCT05233098?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2022-04-04. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT05233098?
The interventions under investigation include: Technetium-99m macroaggregated albumin (Tc-99m MAA) (DEVICE).
Who is sponsoring clinical trial NCT05233098?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.